Literature DB >> 9779996

Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.

H Koga1, N Araki, H Takeshima, T Nishi, T Hirota, Y Kimura, M Nakao, H Saya.   

Abstract

Neurofibromatosis 2 (NF2) is an inherited disorder characterized by a predisposition to multiple intracranial tumors. The protein encoded by the NF2 gene has striking similarities to ezrin, radixin and moesin (ERM) proteins which link membrane proteins to the cytoskeleton. Therefore, it can be speculated that the disruption of cytoskeletal organization by alterations in the NF2 gene is involved in the development of tumors. It has been reported that the majority of NF2 mutations were nonsense or frameshift mutations that result in premature termination of translation. To facilitate the detection of these mutations, we performed protein truncation test and found that 11 of 14 NF2 patients had truncational mutations (79%). Seven of the 11 patients (64%) had a splicing abnormality which lead to absence of exons in the ERM homology domain. To examine the biological significance of the exon-missing mutations in the ERM homology domain, we expressed the wild-type (wt-NF2) and the various mutant NF2s (mu-NF2s) in a fibroblast cell line by using both liposome-mediated transfection and nuclear microinjection of the expression plasmids. The wt-NF2 showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area, whereas the mu-NF2s lacking exons in the ERM homology domain showed granular staining at the perinuclear region without any accumulation at the submembrane region. Microinjection of wt-NF2 cDNA into the nucleus of VA13 cells revealed that wt-NF2 protein induced a progressive elongation of cell processes. Furthermore, cells that expressed mu-NF2 had decreased adhesion, which resulted in detachment from the substratum. These findings suggested that the exon-missing mutations in the ERM-homology domain may affect cell membrane-cytoskeleton signaling and consequently disrupt cell-to-cell or cell-to-matrix interaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779996     DOI: 10.1038/sj.onc.1202010

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Authors:  Hansoo Lee; Donghwa Kim; Han C Dan; Eric L Wu; Tatiana M Gritsko; Chuanhai Cao; Santo V Nicosia; Erica A Golemis; Wanguo Liu; Domenico Coppola; Steven S Brem; Joseph R Testa; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

2.  Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants.

Authors:  Lorena B Benseñor; Kari Barlan; Sarah E Rice; Richard G Fehon; Vladimir I Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

3.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein.

Authors:  M Giovannini; E Robanus-Maandag; M Niwa-Kawakita; M van der Valk; J M Woodruff; L Goutebroze; P Mérel; A Berns; G Thomas
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

4.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

5.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

6.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

7.  Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains.

Authors:  G W Neill; M R Crompton
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

Review 8.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

9.  Mouse models of neurofibromatosis 1 and 2.

Authors:  David H Gutmann; Marco Giovannini
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.